The DIabetic REtinopathy Candesartan Trials
Publications
The Lancet Publications on the effect of candesartan on prevention in Type 1 diabetes (DIRECT-Prevent 1) and progression in Type 1 and Type 2 diabetes (DIRECT-Protect 1 and DIRECT-Protect 2) are now available.
 |
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials |
 |
The effect of the angiotensin receptor blocker candesartan on regression of retinopathy in type 2 diabetes Sjolie AK, Klein R, Chaturvedi N, Porta M, Fuller J, Orchard T, Bilous R and Parving HH Investigative Ophthalmology and Visual Science 2009; 50: E-Abstract 1679 Click here to view the abstract (opens new window) |
|
Effect of candesartan on prevention
(DIRECT-Prevent 1) and progression
(DIRECT-Protect 1) of retinopathy in
type 1 diabetes: randomised,
placebo-controlled trials
Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R and Sjolie AK The Lancet 2008; 372: 1394-1402 Click here to download (opens new window) |
|
Effect of candesartan on progression
and regression of retinopathy in type 2
diabetes (DIRECT-Protect 2): a
randomised placebo-controlled trial
Sjolie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R and Chaturvedi N Lancet 2008; 372: 1385-93 Click here to download (opens new window) |
|
The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics The DIRECT Programme Study Group Journal of the Renin-Angiotensin-Aldosterone System 2005; 6: 25–32 Click here to download |
|
The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme, rationale and study design The DIRECT Programme Study Group and Chaturvedi N Journal of the Renin-Angiotensin-Aldosterone System 2002; 3: 255–261 Click here to download |